ClinicalTrials.gg
Not yet recruitingNCT04003285ALLOUpdated Oct 19, 2026

Allopregnanolone in Chronic Complex Traumatic Brain Injury

A Phase 2 interventional study of Placebo and Allopregnanolone in Traumatic Brain Injury (TBI), sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 62 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment

How we know

Updated Oct 19, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
21 Years to 62 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development — 8 open to participants now, 8 under way, none of them phase 3. Brain Injuries, Traumatic · VA Office of Research and Development.

Planned enrollment
8th of 46
132 · median 61
Started
2026
with 1 other
Phase 2
2 of 55
1 open now
Registered
37th of 55
by date

Among the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, this one is the 8th largest by planned enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2, and was the 37th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

8 of the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 21 Years to 62 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, or all of them as a file.
02

Study summary

This study will determine if allopregnanolone (ALLO) improves depression and pain symptoms in patients who have a history of mild traumatic brain injury (TBI) [primary endpoints]. The investigators will also determine if ALLO improves functional outcome [secondary endpoint]. Participants in this study will receive an intravenous infusion of either ALLO or placebo. Behavioral assessments will be conducted during the infusion and at several time points post-infusion.

Read the detailed description

ALLO is a neurosteroid that exhibits multiple actions highly relevant to the treatment of chronic complex TBI. The investigators' recent human data suggest that ALLO is decreased in patients with TBI, suggesting that ameliorating deficits of this neurosteroid may be clinically therapeutic. In addition, multiple groups have reported ALLO reductions in patients with conditions that frequently co-occur with TBI, including depression and pain disorders. 132 Veterans with a history of mild TBI with co-occurring depression and pain symptoms (chronic complex TBI) will be randomized to either intravenous placebo or ALLO (3 groups/44 participants per group: placebo, lower dose ALLO, higher dose ALLO). Following a loading dose, Veterans will receive placebo or ALLO infusion targeted to achieve serum ALLO levels of 0 nanomolar (nM)(placebo), 50 nM (ALLO lower dose), or 150nM (ALLO higher dose). Behavioral assessments will be conducted during the infusion, post-taper, and 24 hours post-infusion. In addition, the investigators will conduct behavioral assessments 7 days and 14 days post-infusion.

The investigators hypothesize that ALLO will be well-tolerated in patients with complex TBI, and that this intervention may reduce depression and pain symptoms (in addition to potentially improving function).

03

Conditions studied

  • Traumatic Brain Injury (TBI)

Keywords

  • Brain Injuries, Traumatic
  • Depression
  • Pain
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
21 Years to 62 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any ethnic group
  • History of mild traumatic brain injury (TBI) since 2001 and service in the U.S. Military since 9/11/01 (OEF/OIF/OND era)
  • The investigators will adhere to the operational definition of mild TBI suggested by the World Health Organization Task Force, with the exception of seizure and Glasgow Coma Scale score criteria (not available for these participants) with 1 or more of the following:

    • confusion or disorientation
    • loss of consciousness for 30 minutes or less
    • post-traumatic amnesia for less than 24 hours
    • and/or other transient neurological abnormalities such as focal signs, and intracranial lesion not requiring surgery
  • Ability to participate fully in the process
  • Hamilton Depression Rating Scale (HDRS) score 14 (HAM-D range for moderate depression=14-18)
  • Participants will meet , Fifth Edition (DSM-5 criteria for major depressive disorder (by SCID)

    • The presence of psychotic features will be exclusionary
    • Single episodes or recurrent episodes will be permissible for study entry (the investigators will examine treatment responses in those who have had single depressive episodes versus those who have had multiple depressive episodes in exploratory sensitivity analyses
  • BPI (Brief Pain Inventory, Short Form) 'current' pain intensity rating item score 4 (scale of 0-10)

    • Pain must be musculoskeletal in nature
  • No anticipated need to alter psychiatric medications for 14-day duration of study involvement
  • No changes in psychotropic or behavioral interventions during the study or in the 2 weeks prior to study enrollment
  • Concomitant medications for co-occurring medical conditions are permissible for stable medical conditions that are reasonably well-controlled

    • for example, hypertension medications, statins, and oral hypoglycemic medications would generally be permissible if they appear to be effectively treating the underlying condition

Exclusion criteria

Exclusion Criteria:

  • Participants with current suicidal or homicidal ideation necessitating clinical intervention or representing an imminent concern
  • Medications that could potentially confound study outcomes (for example, prednisone) are exclusionary
  • Current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition other than traumatic brain injury (TBI)
  • Female participants who are pregnant or breast-feeding
  • Known allergy to study medication
  • Benzodiazepine, barbiturate, or opioid use within the last 2 weeks is exclusionary
  • Substance use disorder (DSM-5), other than nicotine use disorder
  • A serious medical illness, defined as an illness that requires hospitalization for additional care at the time of screening or one that has required hospitalization in the last month.

    • Any co-occurring medical illness should have a history of stable outpatient management
  • Report of a history of seizures, a history of stroke, a history of prostate cancer (or any other cancer other than non-melanoma skin cancer), a history of myocardial infarction, the presence of congestive heart failure, or any other serious health condition that would likely preclude safe study participation in the medical opinion of the principal investigator (PI) or in consultation with the participant's Primary Care Provider (PCP)/other health care provider
  • Use of oral , a hormone-releasing IUD, or other hormonal supplementation such as estrogen or progesterone, as there is a theoretical risk that a metabolite such as ALLO could potentially impact efficacy of oral contraceptives or estrogen replacement
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Placebo

    ALLO 0 nanomolar (nM) (placebo: loading dose, 4-hour infusion, taper)

    Drug: Placebo

  • Experimental
    ALLO 50 nanomolar (nM)

    ALLO 50 nanomolar (nM) (lower dose ALLO: loading dose, 4 hour infusion, taper)

    Drug: Allopregnanolone

  • Experimental
    ALLO 150 nanomolar (nM)

    ALLO 150 nanomolar (nM) (higher dose ALLO: loading dose, 4 hour infusion, taper)

    Drug: Allopregnanolone

Interventions

  • DrugPlacebo

    ALLO 0 nanomolar (nM) (placebo: loading dose, 4-hour infusion, taper)

  • DrugBrexanoloneStudies of BrexanoloneBrexanolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ALLO 50 nanomolar (nM) (lower dose ALLO: loading dose, 4 hour infusion, taper)

  • DrugBrexanoloneStudies of BrexanoloneBrexanolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ALLO 150 nanomolar (nM) (higher dose ALLO: loading dose, 4 hour infusion, taper)

06

What researchers measure

Primary outcomes

  1. Brief Pain Inventory, Short Form (BPI-SF) Change

    The Brief Pain Inventory, Short Form (BPI-SF) is a self-reported scale that measures the severity of pain and the interference of pain on function. The scores range from 0 (no pain) to 10 (pain as severe as you can imagine). There are 4 questions assessing worst pain, least pain, average pain in the past 24 hours, and pain right now. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). There are 7 questions assessing the interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life.

    Time frame: 6 hours, 24 hours, 7 days, and 14 days

  2. Hamilton-Depression Inventory (HAM-D) Change

    The HAM-D measures the severity of depressive symptoms. It is a checklist of 17 items that are ranked on a scale of 0-4 or 0-2. The range for the total score (which is the sum of the scores of all 17 items) is 0-52; a higher score indicates greater severity of symptoms.

    Time frame: 6 hours, 24 hours, 7 days, and 14 days

Secondary outcomes

  1. Short Form Health Survey (SF-36) Change

    The SF-36 is a health survey with an 8-scale profile embedded in 36 questions that measures physical and mental components of health. Each item is scored on a 0 to 100 range with the lowest and highest possible scores are set at 0 and 100, respectively. All of these items are scored so that a high score defines a more favorable health state.

    Time frame: 6 hours, 24 hours, 7 days, and 14 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.

Of 47 phase 2 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 30. This study's planned 6 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2019
First posted
Jul 1, 2019
StartEst.
Dec 1, 2026was Oct 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Dec 1, 2026
Oct 19, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedParticipants will meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for major depressive disorder (by SCID)
Exclusion criteria
  • EditedCurrent DSM-5 diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition other than traumatic brain injury (TBI)
  • EditedReport of a history of seizures, a history of stroke, a history of prostate cancer (or any other cancer other than non-melanoma skin cancer), a history of myocardial infarction, the presence of congestive heart failure, or any other serious health condition that would likely preclude safe study participation in the medical opinion of the principal investigator (PI) or in consultation with the participant's Primary Care Provider (PCP)/other health care provider
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Start date Oct 1, 2026→Dec 1, 2026
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants will meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for major depressive disorder (by SCID)
    Exclusion criteria
    • EditedCurrent DSM-5 diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition other than traumatic brain injury (TBI)
    • EditedReport of a history of seizures, a history of stroke, a history of prostate cancer (or any other cancer other than non-melanoma skin cancer), a history of myocardial infarction, the presence of congestive heart failure, or any other serious health condition that would likely preclude safe study participation in the medical opinion of the principal investigator (PI) or in consultation with the participant's Primary Care Provider (PCP)/other health care provider
    + 4 other changes: identifiers, verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04003285
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Christine E Marx, MD MA
Contact
christine.marx@va.gov
(919) 286-0411 ext. 5112
Christine E. Marx, MD MA
principal investigator · Durham VA Medical Center, Durham, NC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexanolone

Start the discussion